TCGA-XF-A9SV-01A-21R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.74638633
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- PROTEIN_SECRETION+0.340
- COAGULATION+0.300
- TGF_BETA_SIGNALING+0.290
- ANDROGEN_RESPONSE+0.260
- PANCREAS_BETA_CELLS+0.250
- BILE_ACID_METABOLISM+0.240
- PEROXISOME+0.220
- CHOLESTEROL_HOMEOSTASIS+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.490
- INTERFERON_GAMMA_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.410
- IL6_JAK_STAT3_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.370
- MITOTIC_SPINDLE-0.310
- MYC_TARGETS_V2-0.270
- INFLAMMATORY_RESPONSE-0.250
- E2F_TARGETS-0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518184 | — | F | 0.804 |
| 2 | MBCProject_0067_T1_RNA | — | A | 0.787 |
| 3 | SRR8518241 | — | F | 0.787 |
| 4 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.783 |
| 5 | SRR8518414 | — | C | 0.770 |
| 6 | TCGA-E2-A1IN-01A-11R-A13Q-07 | — | C | 0.766 |
| 7 | SRR8613754 | — | F | 0.764 |
| 8 | TCGA-2F-A9KQ-01A-11R-A38B-07 | — | — | 0.760 |
| 9 | MBCProject_0504_T1_RNA | — | A | 0.755 |
| 10 | TCGA-S3-AA14-01A-11R-A41B-07 | — | A | 0.754 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |